HER-2, notch, and breast cancer stem cells: targeting an axis of evil.
Where this comes from
- Record sourced from PubMed, PMID 19276254.
- Also identified by DOI 10.1158/1078-0432.CCR-08-3087.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Increasing evidence indicates that tumor-initiating (cancer stem) cells may contribute to treatment resistance and relapse, suggesting that improved clinical outcome will require effective targeting of this cell population. Recent studies suggest that the remarkable clinical efficacy of trastuzumab may relate to its ability to target cancer stem cell populations.
Medical subject headings
- Antibodies, Monoclonal
- Breast Neoplasms
- Cell Line, Tumor
- Erb-b2 Receptor Tyrosine Kinases
- Receptors, Notch